## For Research Use Only

## HER2/ErbB2 Monoclonal antibody

Catalog Number:60311-1-lg 6 Publications



Basic Information	Catalog Number: 60311-1-lg	GenBank Accession Number: BC 156755	Purification Method: Protein A purification	
	Size:	GeneID (NCBI):	CloneNo.:	
	150ul , Concentration: 1500 ug/ml by		1B12A7	
	Nanodrop;	UNIPROT ID:	Recommended Dilutions:	
	Source:	P04626	IHC: 1:800-1:3200	
	Mouse	Full Name:	IF-P: 1:50-1:500 FC: 0.20 ug per 10^6 cells in a 100 µl	
	lsotype: lgG2b	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,	suspension	
	Immunogen Catalog Number:	neuro/glioblastoma derived oncogene homolog (avian)		
	AG16463	Calculated MW:		
		1255 aa, 138 kDa		
Applications	Tested Applications:	Positive Controls:		
	IHC, IF-P, ELISA	IHC : human breast cancer tissue,		
	Cited Applications: IHC, IF	IF-P : human breast cancer tissue,		
	Species Specificity: human	FC : SK-BR-3 cells,		
	Cited Species: human			
	Note-IHC: suggested antigen r TE buffer pH 9.0; (*) Alternativ retrieval may be performed w buffer pH 6.0	vely, antigen		
Background Information	TE buffer pH 9.0; (*) Alternativ retrieval may be performed w buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pu	rely, antigen ith citrate nsmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor fi cing kinase-mediated activation of c rotein kinase and phosphatidylinosit ported in numerous cancers, includir	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or Ig breast and ovarian tumors. HER2 is a	
	TE buffer pH 9.0; (*) Alternative retrieval may be performed we buffer pH 6.0 HER2, ErbB2, and Neu is a 185-kDa tra- receptor family of receptor tyrosine ke factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pi overexpression of HER2 have been re therapeutic target for the treatment of	rely, antigen ith citrate nsmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor fi cing kinase-mediated activation of c rotein kinase and phosphatidylinosit ported in numerous cancers, includir	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or Ig breast and ovarian tumors. HER2 is a	
	TE buffer pH 9.0; (*) Alternative   retrieval may be performed we   buffer pH 6.0   HER2, ErbB2, and Neu is a 185-kDa transference   receptor family of receptor tyrosine ke   factors. However, it does bind tightly   stabilizing ligand binding and enhan   those involving mitogen-activated performed to the treatment of   Author Pub	rely, antigen ith citrate insmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor fi cing kinase-mediated activation of c rotein kinase and phosphatidylinosit ported in numerous cancers, includir f breast cancer and other carcinomas	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or g breast and ovarian tumors. HER2 is a	
	TE buffer pH 9.0; (*) Alternative retrieval may be performed we buffer pH 6.0HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pi overexpression of HER2 have been re therapeutic target for the treatment ofAuthorPub Yanlin WuYanlin Wu301	nely, antigen ith citrate insmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor f cing kinase-mediated activation of c rotein kinase and phosphatidylinosit ported in numerous cancers, includir f breast cancer and other carcinomas med ID Journal	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or gbreast and ovarian tumors. HER2 is a Application	
	TE buffer pH 9.0; (*) Alternative retrieval may be performed we buffer pH 6.0HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine ke factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pi overexpression of HER2 have been re therapeutic target for the treatment ofAuthorPub Yanlin Wu301 366	rely, antigen ith citrate insmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor fi cing kinase and phosphatidylinosit ported in numerous cancers, includir f breast cancer and other carcinomas med ID Journal 27983 Oncol Lett	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or g breast and ovarian tumors. HER2 is a Application IHC	
Notable Publications	TE buffer pH 9.0; (*) Alternative retrieval may be performed we buffer pH 6.0HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine ke factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pi overexpression of HER2 have been re therapeutic target for the treatment ofAuthorPub Yanlin Wu301 Fei XingFei Xing366 Xin Zhou	rely, antigen ith citrate   insmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor f cing kinase-mediated activation of c rotein kinase and phosphatidylinosit ported in numerous cancers, includin f breast cancer and other carcinomas   med ID Journal   27983 Oncol Lett   27608 Mol Cancer	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or g breast and ovarian tumors. HER2 is a	
Notable Publications	TE buffer pH 9.0; (*) Alternative retrieval may be performed we buffer pH 6.0HER2, ErbB2, and Neu is a 185-kDa tra receptor family of receptor tyrosine ke factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pi overexpression of HER2 have been re therapeutic target for the treatment ofAuthorPub Yanlin Wu301 366	rely, antigen ith citrate   Insmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor ficing kinase-mediated activation of ci- ortein kinase and phosphatidylinositi ported in numerous cancers, includin f breast cancer and other carcinomas   med ID Journal   27983 Oncol Lett   27968 Mol Cancer   27954 J Cancer	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or g breast and ovarian tumors. HER2 is a	
Background Information Notable Publications	TE buffer pH 9.0; (*) Alternative retrieval may be performed we buffer pH 6.0   HER2, ErbB2, and Neu is a 185-kDa trareceptor family of receptor tyrosine k factors. However, it does bind tightly stabilizing ligand binding and enhan those involving mitogen-activated pi overexpression of HER2 have been retherapeutic target for the treatment of Yanlin Wu   Author Pub   Yanlin Wu 301   Fei Xing 366   Xin Zhou 321   Storage: Storage Buffer:	rely, antigen ith citrate   Insmembrane glycoprotein member inases. It has no ligand-binding dom to other ligand-bound EGF receptor ficing kinase-mediated activation of corotein kinase and phosphatidylinosit ported in numerous cancers, includin f breast cancer and other carcinomas   med ID Journal   27983 Oncol Lett   27608 Mol Cancer   27954 J Cancer   er shipment. % glycerol, pH7.3	ain and therefore cannot bind growth amily members to form a heterodimer, lownstream signalling pathways, such a ol-3 kinase. Amplification and/or g breast and ovarian tumors. HER2 is a	


T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free

in USA), or 1(312) 455-8498 (outside USA)

E: proteintech@ptglab.com W: ptglab.com

Group brand and is not available to purchase from any other manufacturer.


## Selected Validation Data




1x10^6 SK-BR-3 cells were surface stained with 0.2 µg HER2/ErbB2 Monoclonal antibody (60311-1-Ig, Clone: 1B12A7) and Coralite® Plus 647-Goat Anti-Mouse Recombinant Secondary Antibody (H+L) (Cat.NO.RGAM005). Mouse IgG2b isotype control (66360-3-Ig, Clone: 11B8C4) was parallel stained as control. Cells were not fixed.




Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 60311-1-Ig (HER2/ErbB2 antibody) at dilution of 1:1600 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 60311-1-Ig (HER2/ErbB2 antibody) at dilution of 1:1600 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (4% PFA) fixed human breast cancer tissue using 60311-1-lg (HER2/ErbB2 antibody), at dilution of 1:200 and CoraLite® 488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).



Immunofluorescent analysis of (4% PFA) fixed human breast cancer tissue using 60311-1-Ig (HER2/ErbB2 antibody), at dilution of 1:200 and CoraLite@488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).



Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 60311-1-Ig (HER2/ErbB2 antibody) at dilution of 1:40000 (under 10x Lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).